StreetAlpha.app
Home › Stocks › XLO

Xilio Therapeutics, Inc. (XLO)

$7.54
▼ −2.08%
LAST CLOSE · NOV 17

Xilio Therapeutics develops masked immunotherapy treatments that activate inside tumors to treat cancer. It last closed at $7.54 on Nov 17, down 2.08% on the day.

AI Auto Pilots
Is XLO in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$55.0M
+73.0% vs a year ago
Net income
−$11.5M
−20.9% margin
Free cash flow
−$57.6M
−104.8% margin
Operating margin
−74.9%
−$41.2M operating income
Valuation
Market cap
$53.3M
7.1M shares
P/E
–
Price to sales
1.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$122.2M
At Sep 30
Shareholder equity
$68.2M
Shares outstanding
7.1M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $6.3M$6.3MFY2024FY2025: $43.8M$43.8MFY2025

From XLO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated XLO in the past 90 days, not enough for a consensus
Average 12-month target
$16.00
▲ 112.2% upside

Based on 1 analyst who set a price target on XLO in the past 90 days. The average target is $16.00, with a high of $16.00 and a low of $16.00, compared with the last close of $7.54.

Low $16.00Avg $16.00High $16.00
Blue marker: last close $7.54
Highest target$16.00
Average target$16.00
Lowest target$16.00
Latest rating changes
Raymond JamesInitiated
Oct 21Buy$16
DateFirmActionRatingPrice target
Oct 21Raymond JamesInitiatedBuy$16
Loading…

Technical Analysis

XLO · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 8% below its 20 day and 15% below its 50 day average. It is 12% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the swing low (Jun 5) at $7.53, and the nearest resistance the Pivot R1 at $7.87.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 8.4%/day
Key levels
$11.3052 week high+49.9%
$8.86100 day average+17.5%
$8.6450 day average+14.6%
$8.48200 day average+12.5%
$8.33Swing high (Jun 8)+10.5%
$8.1620 day average+8.2%
$7.87Pivot R1+4.4%
$7.54Last close
$7.53Swing low (Jun 5)−0.1%
$7.51Pivot−0.4%
$7.17Pivot S1−4.9%
$6.4752 week low−14.2%
Indicators
RSI (14)36.01Weak, oversold below 30Neutral
MACD-0.18Below its signal lineBearish
Stochastic36.1Middle of its rangeNeutral
ADX (14)27.4Trending down
Williams %R-74.9Oversold below −80, overbought above −20Neutral
CCI (20)-117.4Oversold below −100, overbought above 100Oversold
Rate of change−13.1%Change over 10 sessionsBearish
ATR (14)$0.63Typical daily range, 8.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for XLO

What happened before

See how XLO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow XLO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How XLO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in XLO in the last 90 days.

Loading…

See today’s whale options flow across the market →

XLO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲16 buying vs 7 selling
  • ▲Held by funds +5.3 pts
  • ▲Funds holding +4
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding3026+15.4%
In funds' top 10110.0%
Held by funds53.5%48.2%+5.3 pts
New / increased7 / 910 / 4+14.3%
Reduced / sold out4 / 34 / 7−36.4%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See XLO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether XLO is in one of them and how their past XLO trades turned out.

XLO in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered XLO in an article yet. Here's the latest on the wider market.

About Xilio Therapeutics

Xilio Therapeutics is a biotechnology company that discovers and develops cancer immunotherapies designed to stay inactive until they reach tumors. Enzymes found in tumors remove the mask, which aims to limit activity in healthy tissue. Its pipeline includes a masked IL-2 fusion protein and masked T cell engagers, and it has partnerships with AbbVie and Gilead. The company is based in Waltham, Massachusetts, and is developing its treatments for patients with cancer.

Headquarters
Waltham, MA